uv1 vaccine
Vaccineexperimental
Clinical trial activity
6 trials · 19 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02275416)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- uv1 vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05344209 | Phase 2 | Aug 12, 2022 | Helse Fonna, Helse Forde, Helse Møre og Romsdal HF, Northern Norway Regional Health Authority, Norwegian University of Science and Technology, Oslo Metropolitan University, University Hospital of North Norway, University of Bergen, University of Oslo, University of Stavanger, Vestre Viken Ringerike Sykehus |
| NCT05075122 | Phase 2 | Aug 2, 2021 | https://www.researchgate.net/profile/Axel-HinkeCCRC Cancer Clinical Research Consulting (Düsseldorf, Germany, Johannes Gutenburg University, Martin Luther University, Ultimovacs AS, University of Halle |
| NCT04382664 | Phase 2 | May 15, 2020 | Saint John's Health Center - John Wayne Cancer Institute (JWCI), Ultimovacs AS |
| NCT04300244 | Phase 2 | Mar 15, 2020 | Bristol-Myers Squibb, Ultimovacs AS, University of Oslo |
| NCT03538314 | Phase 1 | May 31, 2018 | Ultimovacs AS |
| NCT02275416 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | Osaka University, Ultimovacs AS |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (19)
19 organizations
Page 1 / 1